Overview

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Henlius Biotech